Get the Stockscreener App
184.74
1.40%
-2.63
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $184.74, with a volume of 1.79M.
It is down -1.40% in the last 24 hours and down -7.97% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$187.37
Open:
$185.45
24h Volume:
1.79M
Relative Volume:
0.76
Market Cap:
$286.50B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
55.48
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-2.64%
1M Performance:
-7.97%
6M Performance:
+124.20%
1Y Performance:
+162.01%
1-Day Range:
$184.01
$187.18
1-Week Range:
$181.73
$190.59
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors - CoinCentral
FDA advisory panel recommends AstraZeneca’s Truqap for PTEN-deficient prostate cancer - Investing.com Nigeria
FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo - Stock Titan
FDA panel supports AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient prostate cancer - Stock Titan
FTSE 100 drops in thin trading as NatWest, AstraZeneca weigh - Moneycontrol.com
AstraZeneca wins FDA AdCom backing for Truqap (AZN:NYSE) - Seeking Alpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters - Benzinga
AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1 - Value The Markets
AstraZeneca Faces Setback as Drug Review Stirs Market Focus - Kalkine Media
AstraZeneca shares drop after US regulators vote against breast cancer drug - marketscreener.com
Why is AstraZeneca stock down today? - Traders Union
AstraZeneca falls as FDA advisers reject breast cancer drug use - Proactive financial news
AstraZeneca Shares Weaken After FDA Panel Rejects Camizestrant - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.58 a shareEarnings Preview - TradingView
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote -- Update - marketscreener.com
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug - Reuters
AstraZeneca shares dip after US regulatory panel rejects breast cancer drug - marketscreener.com
US FDA Committee Votes Against Combination Formulation Featuring AstraZeneca's Camizestrant - marketscreener.com
AstraZeneca's Truqap Recommended by US FDA's Oncologic Drugs Committee - marketscreener.com
AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
Alger Growth & Income Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap recommended by FDA advisory committee for prostate cancer - marketscreener.com
ASTRAZENECA : Jefferies reiterates its Buy rating - marketscreener.com
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug - marketscreener.com
FDA panel rejects risk-benefit profile of AstraZeneca cancer drug - Reuters
FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug - Bloomberg.com
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom - 24/7 Wall St.
FDA panel votes against backing AstraZeneca's breast cancer drug - marketscreener.com
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports - marketscreener.com
AstraZeneca Earnings: Off to a Great Start, With Major Readouts Expected Throughout the Year - Morningstar
Astrazeneca exercises option for Pinetree’s PTX-299 - BioWorld News
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts - Proactive financial news
AstraZeneca Outlook Strengthens on Pipeline Momentum - Kalkine Media
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - Quantisnow
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
EBIT per share of AstraZeneca PLC – HAM:ZEG - TradingView
Astrazeneca injects £300m into UK sites - marketscreener.com
Astrazeneca Q1 Earnings Call Highlights - Yahoo Finance
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
Astrazeneca (NYSE:AZN) Issues Quarterly Earnings Results - MarketBeat
AstraZeneca CEO says US MFN policy will have substantial impact on European drug launches, pricing - marketscreener.com
Correction to AstraZeneca Update - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):